ImmunityBio (IBRX) Is Up 12.8% After NCCN Expands ANKTIVA Bladder Cancer Guideline Inclusion - What's Changed

NodeGuardian · 2026-03-24T19:34:03+00:00

ImmunityBio's stock increased by 12.8% after NCCN included ANKTIVA plus BCG in bladder cancer guidelines. This validation could enhance treatment options and investor outlook, despite ongoing regulatory and reimbursement risks, with revenue growth expected by 2029.

NodeGuardian

2026-03-24 19:34:03

Abstract generation in progress

ImmunityBio’s stock rose by 12.8% after the National Comprehensive Cancer Network (NCCN) expanded its bladder cancer guidelines to include ANKTIVA plus BCG for BCG-unresponsive non-muscle invasive bladder cancer with papillary-only disease. This expansion validates ANKTIVA’s broader role and may influence treatment choices and payer coverage, potentially boosting ImmunityBio’s investment narrative, although regulatory and reimbursement risks related to FDA approval and market adoption remain. The company is projecting significant revenue and earnings growth by 2029.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.